Our Door to Asia and the World
Our “youngest” network site in Shanghai is another representation of our dedication to global customer support. We are pioneering CMO in China by leading the CMO trial with the authorities and are also the first multi-national pharmaceutical company to bring over 35 years of experience to China, to better serve both the patients and the biopharmaceutical industry. For Boehringer Ingelheim BioXcellence™, the goal is nothing less than to become a leader for contract development and manufacturing of monoclonal antibodies and recombinant proteins in China.
After starting operation in 2014, the Shanghai site received another addition in 2017. The Oasis GMP facility has up to 2 x 2,000 L manufacturing scale including Fill & Finish, with both Oasis and the pre-existing BioLab based on a globally established disposable technology concept. The result:
Smooth project transfers to China and anywhere in our network.
|History:||Operating facility since 2014|
|Employees:||more than 100|
|Standout Characteristics:||Flexible, fully disposable GMP facility|
|Technology:||Mammalian cell culture
Upstream and downstream process optimization
Clinical and commercial production
Global Boehringer Ingelheim quality standards
Global Boehringer Ingelheim information protection processes and framework
Monoclonal antibodies and fusion proteins
cGMP facilities are certified by the National Medical Products Administration of China (NMPA, formerly known as CFDA: China Food and Drug Administration).
Our operations and quality systems meet the cGMP requirements of international regulatory authorities.